Abstract: Novel combined vaccine composition preferentially for administration to adolescents are provided, comprising a hepatitis B viral antigen and a herpes simplex viral antigen and optionally in addition one or more of the following: an EBV antigen, a hepatitis A antigen or inactivated attenuated virus, an HPV antigen, a V2V antigen, a HCMV antigen, a Toxoplasma gondii antigen. The vaccine compositions are formulated with an adjuvant which is a preferential stimulator of TH1 cell response such as 3D-MPL and QS21.
Type:
Grant
Filed:
August 23, 2002
Date of Patent:
August 23, 2005
Assignee:
SmithKline Beecham Biologicals S.A.
Inventors:
Jean Stephenne, Martine Anne Cecile Wettendorff